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ABSTRACT OF THESIS: 
AGGRESSIVE DIURESIS AND SEVERITY-ADJUSTED LENGTH OF HOSPITAL 
STAY IN ACUTE CONGESTIVE HEART FAILURE PATIENTS 
To see if aggressive diuresis in first twenty four hours is associated with a 
comparable number of total days in the hospital as compared to non-aggressive diuresis.  
In this retrospective cohort study, we compared the length of hospital stay of consecutive 
patients admitted in one year based on their diuresis during the first twenty-four hours of 
hospitalization: aggressive diuresis (group 1) i.e. >2400mL versus non-aggressive 
diuresis (group 2) i.e. ≤ 2400mL urine output. Patients were excluded if in cardiogenic 
shock, had creatinine level above 3 mg/dL on admission, or on dialysis. A total of 194 
patients were enrolled (29 in group 1 and 165 in group 2 respectively). The Kaplan-Meier 
estimate of the median cumulative proportion of patients still hospitalized for the group 1 
was 4 days and in group 2 was 5 days (log-rank test; P=0.67). In univariate analysis, Cox 
PH regression showed unadjusted hazard rate of discharge from hospital was slightly 
higher in group 1 than group 2 but was statistically non-significant (HR=1.08; P=0.70). 
In multivariate Cox model analysis, creatinine at the time of admission when greater than 
1.6mg/dL (P=0.75), LVEF (P= 0.14), total twenty-four hours dose of intravenous 
Furosemide given (P=0.98) and interaction between Furosemide dose and Creatinine 
level (P=0.79) were not significant predictor of hospital discharge. Adjusted hazard rate 
for discharge from hospital was 12% higher in group 1 than group 2 but still statistically 
non-significant (HR=1.12; P=0.60). Since the length of hospital stay is similar between 
two groups, we suggest the goal of diuresis to be less than 2400mL in first twenty four 
hours to prevent excessive dehydration. 
Keywords: Aggressive Diuresis, Furosemide, length of hospital stay, Chronic Kidney 
Disease 
Muhammad Umer Butt M.D.________ 
Signature 
_________April 30, 2018______ 
Date 
ii 
 AGGRESSIVE DIURESIS AND SEVERITY-ADJUSTED LENGTH OF 
HOSPITAL STAY IN ACUTE CONGESTIVE HEART FAILURE 
PATIENTS 
 By  
Muhammad Umer Butt M.D. 
David Mannino M.D.__________ 
Director of Thesis 
David Mannino M.D.__________ 
Director of Graduate Studies 
______April 28, 2018_________ 
Date 
iii 
ACKNOWLEDGEMENTS: 
 Special thanks to Hany A. Abdel Messeh M.D, Internist Mercy Hospital of South 
Buffalo for the collection and sharing of data. Dr. David Mannino, my program director 
and advisor for time, patience, and support. Dr. Kathi L.H. Harp and Dr. Li Chen for their 
time spent providing me with detailed feedback on this project on multiple occasions. Dr. 
Susan Smyth for advising and research grant assistance. Claude S. Elayi M.D. incredibly 
talented and selfless cardiac Electrophysiologist for continuous input and critical 
appraisal of the final manuscript. 
This research project was supported by the National Institutes of Health under 
Ruth L. Kirschstein National Research Service Award (T32HL091812) from National 
Heart, Lung, and Blood Institute (NHLBI). 
Last but not least, I would like to thank my wife Anam Butt M.D. and my son 
Ezaan Umer Butt for selflessly supporting me every day in all I do. I could not have 
gotten here without you. Love you both so incredibly much. 
iv 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .................................................................................................... iii 
LIST OF TABLES .................................................................................................................... v 
LIST OF FIGURES .................................................................................................................. vi 
CHAPTER 1: INTRODUCTION ............................................................................................. 1 
1.1 BACKGROUND ............................................................................................................ 1 
1.2 OBJECTIVES ................................................................................................................. 3 
CHAPTER 2: STUDY DESIGN ............................................................................................... 4 
2.1 STUDY DESIGN AND POPULATION......................................................................... 4 
2.2 INCLUSION CRITERIA.................................................................................................5 
2.3 EXCLUSION CRITERIA................................................................................................6 
2.4. OUTCOME ASSESSMENT ......................................................................................... 6 
2.5 EXPOSURE ASSESSMENT ..........................................................................................6 
2.6 COVARIATE ASSESSMENT   .................................................................................... 7 
2.7 SAMPLE SIZE AND POWER   .................................................................................... 10 
2.8 DATA MANAGEMENT.............................................................................................. 12 
2.9 STATISTICAL ANALSYSIS PLAN:   ........................................................................ 13 
CHAPTER 3: RESULTS ........................................................................................................ 17 
CHAPTER 4: DISCUSSION .................................................................................................. 30 
CHAPTER 5: LIMITATION.................................................................................................. 34 
CHAPTER 6: CONCLUSION ............................................................................................... 34 
REFERENCES........................................................................................................................ 36 
VITA ....................................................................................................................................... 39 
v 
LIST OF TABLES 
Table 1: Variable Description ..............................................................................................................8 
Table 2: Characteristics of Patients…...................................................................................... 19 
Table 3: Multiple Linear Regression model with 24 Hour Urine output regressed on dose of 
Furosemide, Creatinine at the time of admission. .................................................................... 23 
Table 4: Summary of Kaplan – Meir Estimate for Cohort-...................................................... 25 
Table 5: Survival Characteristics of subgroups …................................................................... 26 
Table 6: Univariate Cox Proportional Hazards Regression Model Showing effect of Aggressive 
Diuresis on Risk of Discharge from Hospital............................................................................28 
Table 7: Multiple Cox Proportional Hazards Regression Model ..............................................29 
vi 
LIST OF FIGURES 
Figure 1: Flow chart of patients’ enrollment in the study..............................................16 
Figure 2: Scatter plot with regression line for relationship between total dose of 
Furosemide used in first twenty-four hours .................................................................22 
Figure 3: Comparison of length of stay in hospital (days) for patient with acute 
Congestive Heart Failure with urine output less than or equal to 2400mL and greater 
than 2400mL in first twenty-four hours....................................................................... 27 
1 
1.1 BACKGROUND: 
 Heart failure is a clinical syndrome associated with reduced effective blood 
pumping capacity of the heart. Congestive Heart Failure(CHF) is a global pandemic 
affecting at least 26 million people worldwide and 6.5  million people in the US  with age 
≥ 20 years.1 Increase in incidence and prevalence of CHF is not due to the failure in 
treatment but an increased survival in the aging population who suffer from Acute 
Coronary Syndrome and related diseases of the heart. Heart failure is the most common 
diagnosis related reason for hospitalization in ≥ 65-year-old patients. The total direct cost 
of the CHF patients has been estimated to be around $ 20 to $ 40 billion annually with the 
mean estimated cost of each hospitalization of $14,631. Economic burden of CHF is 
further compounded by about 25% readmission rate within 30 days.2 National average 
length of hospital stay is around 6 to 8 days.3,4 Medicare reimbursement for CHF patient 
is linked to the length of hospital stay and quality measures.4 There are situations during 
uncomplicated hospital admission, where expenses borne by the hospital exceed the 
reimbursement from insurance companies incurring undesirable financial penalties.  
There is an inherent desire to shorten the length of hospital stay without increasing the 
morbidity, mortality, and hospital re-admission rate. 
 Acute CHF is associated with on average up to 15 to 20 liters of extra fluid in the 
body. There are multidimensional approaches in the treatment of CHF depending on the 
etiology, type, and severity of CHF, but diuretics have been the time-tested cornerstone 
of every treatment.  Loop diuretics are the effective first line diuretic therapy.5 Relieving 
congestion is the primary goal, but it is not always free from adverse effects of 
hypotension, worsening of renal function, electrolytes abnormality, and arrhythmias. 
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There are no clinical trials that define the ideal diuretic dose, thus, dosing is largely based 
on iterative increases with observation of patients for urine output, subjective assessment 
of patient fluid overload status, ejection fraction, home dose of diuretics, blood pressure 
at presentation, concurrent use of other medications, comorbidities, and renal function. 
Practically speaking, after hospital admission with acute congestive heart failure, the 
patient is empirically given the first dose of diuretic in the emergency room. As the 
patient is reassessed and given a subsequent dose of a loop diuretic, the relief of 
symptoms and ultimately the length of hospital stay depend partly on weight change or 
indirectly urine output. A common observation is that a high dose of diuretic does not 
necessarily translate into greater urine output in many situations, as numerous variables 
confound this relationship i.e. tolerance to diuretics, decrease GI absorption, 
hyperchloremia, and the severity of CHF and renal dysfunction at baseline or during the 
hospital stay. The goal of therapy is to maximize the urine output, but too much diuresis 
in a short time can lead to adverse effects.  All treatments are directed towards starting 
certain adequate dose loop diuretic, but there is no magic number. The dose of diuretic 
given is merely one of the factors that can affect subjective relief of symptoms and length 
of hospital stay, but final urine output achieved by a diuretic dose has more intuitive and 
deterministic role practically.6 It is the eventual objective outcome depicting the effect of 
a diuretic. Thus, adequate diuresis achieved initially irrespective of starting dose of 
diuretic used can be assumed to have a direct role in relieving fluid overload symptoms. 
The total dose of diuretic given in first twenty-four hours which is highly variable likely 
helps to choose the subsequent tolerable dose, but it is only one of the factors determining 
the amount of urine if comorbidities or adverse effect of diuresis do not complicate the 
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course of the hospital. The DOSE trial addressed  the primary question  if symptomatic 
improvement, worsening of renal function is related to low vs. high dose of loop diuretic 
given as continuous vs. bolus dose protocols.7 This study did not find any difference in 
primary endpoint as well as its prespecified secondary endpoint of any difference in the 
length of hospital stay between four groups. But the study was not powered to detect the 
difference in the length of hospital stay, more so ever there was no comparison of urine 
output between the groups.  However, two observational studies, first by Howard and 
Dunn and later by Li and Hong found that aggressive diuretic therapy to achieve greater 
than 100mL/hour  (≥ 2400mL/ 24)  of urine leads to a shorter length of hospital stay.3,8 
Therefore, there are conflicting results between the dose of diuretic, subsequently urine 
output and length of hospital stay. Numerous studies have addressed the relationship 
between the dose of diuretic and length of hospital stay, but here we rather propose to 
examine the more direct relationship between the amount of diuresis in first twenty-four 
hours irrespective of dose of a loop diuretic and disease severity-adjusted length of 
hospital stay. 
 
1.2 OBJECTIVES:  
PRIMARY OBJECTIVE  
The dose of diuretic is directly related to the urine output if there are no untoward 
effects and other disease severity associated predictors are accounted for. The higher the 
urine output, the earlier the relief of symptoms and the shorter the length of hospital stay. 
Since fluid overload is the primary pathological mechanism in acute congestive heart 
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failure patients, theoretically, diuresis driven by urine output itself achievable by any 
dose of diuretic would be better able to determine the decongestion and length of hospital 
stay. Patients will be divided into aggressive diuretic therapy group and non-aggressive 
diuresis group by the criterion used by Howard and Dunn.3 Expectantly it will be of 
interest to see if higher urine output leads to a shorter hospital stay.  
Hypothesis: 
    Patients who had aggressive diuresis in first twenty-four hours (urine output ≥ 
2400mL/24 hour) will have a different a length of hospital stay than patients who had 
less-aggressive diuresis. (urine output < 2400mL/24hour) irrespective of the dose of loop 
diuretics. 
DESCRIPTIVE OBJECTIVE:  
1 Study the association of dose of diuretics in first twenty-four-hour urine output using 
univariate and multivariate analysis, defining the predictors of association. 
2 Study the risk of developing adverse effects as arrhythmia, worsening of renal function, 
electrolyte abnormality, and death in aggressive and non-aggressive diuretic therapy 
group. 
STUDY DESIGN AND METHODS: 
2.1 STUDY DESIGN AND POPULATION: 
  To examine the association between the amount of urine output in first twenty-
four hours in acute CHF patients and the total length of hospital stay we propose to 
conduct a retrospective cohort study utilizing data from Mercy Hospital of South Buffalo, 
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affiliated with the State University of Buffalo. This hospital has a capacity of 450 beds 
and serves a population of approximately1,500,000. Acute medical care of CHF is 
provided predominantly by residents, fellows, internists, and cardiologists. Patients 
admitted to the acute general medical wards and Cardiac Care Units either as a first 
diagnosis or an exacerbation of pre-existing HF between 2014 and 2015 will be 
prospectively identified by using International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] diagnosis code. Detailed data will be recorded 
retrospectively from the hospital records of each index hospital admission. The study will 
not include any vulnerable population. 
2.2 INCLUSION CRITERIA: 
Patients included will be 18- 80 years old who presented with new onset or 
chronic CHF diagnosed by elevated filling pressures, indicated by one symptom and one 
physical sign regardless of ejection fraction. 
• Symptoms: Dyspnea at rest, in the supine position, or immediately upon 
routine activity within one room; abdominal discomfort, severe anorexia, 
or nausea without apparent cause other than hepatosplanchnic congestion. 
• Signs: Jugular venous pressure elevation >10 cm above the right atrium; 
hepatomegaly, ascites, or edema in the absence of other apparent causes; 
rales greater than 1/3 lung fields and/ or pleural effusion.   
• Imaging documentation: of congestive heart failure including pulmonary 
vascular congestion in chest x-ray will supplement the signs and 
symptoms. 
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2.3 EXCLUSION CRITERIA: 
• Patients will be excluded if creatinine level greater than 3 mg/dl on admission or 
if the patient is on dialysis.  
• Patient will also be excluded if in cardiogenic shock defined as systolic blood 
pressure below 90 mm Hg and requiring the use of inotropic medication or 
mechanical support.  
• Patient will be excluded if they had any acute concurrent medical illness as Acute 
Coronary Syndrome, COPD or Asthma Exacerbation. 
2.4 OUTCOME ASSESSMENT:  
It is the time to event analysis.  The event of interest (endpoint) will be discharge 
from the hospital. Time origin is the date of admission to the hospital. Survival time is the 
length of hospital stay, i.e. time interval in days measured from the day of admission to 
final discharge from the hospital. We anticipate we will be observing the event in all the 
patients admitted to the hospital within 30 days of admission (patient follow up time). If 
the event is not recorded in medical records as day of discharge from the hospital, then 
observation will be considered censored at last day of available record in the system. 
Patient will also be censored if patient died of any cause during hospitalization or if the 
patient is still in the hospital at the end of the calendar study time of study December 31, 
2015.  
 
 
 
 
7 
  
2.5 EXPOSURE ASSESSMENT:    
Exposure of interest is the after hospitalization first twenty-four hours maximum 
urine output (in milliliters). It will involve abstraction of the data from medical records 
within first twenty-four hours when the patient was either in the Emergency Room, 
medical floor or Cardiac Care Unit. Urine output initially will be measured as a 
continuous variable but later it will be dichotomized into two categories as aggressive 
diuretic therapy group (with urine output greater than 2400mL/1st 24 hours) and non- 
aggressive diuretic therapy group (with urine output less than or equal to 2400mL/1st 24 
hours). 
2.6 COVARIATE ASSESSMENT:   
Data for covariates will be abstracted from the medical record (see table Variable 
Description table 1).  Apart from demographic characteristics, data will be obtained about 
the type of CHF i.e. systolic or diastolic type of CHF, Ejection Fraction (EF) of the left 
ventricle, systolic blood pressure and serum creatinine at the time of admission. 
Creatinine will be further dichotomized into two categories to define stages of Chronic 
Kidney Disease (CKD) i-e less than or equal to Stage III CKD (lesser than 1.6mg/dL) and 
equal or greater than Stage IV CKD (higher than 1.6mg/dL).  The total maximum dose of 
loop diuretics exclusively Furosemide given either as an intravenous bolus or continuous 
intravenous infusion in first twenty-four hours will be noted. Information regarding any 
adverse events occurred during hospitalization will be recorded which will include death, 
arrhythmia, worsening of renal function and hypotension. 
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Table 1 Variable Description 
Variable 
Name  
Description of Variable Type of 
Variable 
ID  Patient ID  
AGE Age in years at the time of admission. Continuous 
SEX Gender of the patient 
0=Female 
1=Male 
 
Dichotomous 
RACE Race of the patient 
0= white  
1=non-white 
 
Dichotomous 
EVENT Event of interest is the discharge from the 
hospital. 
1= Discharge from the hospital. 
0= Censored. No record of discharge from the 
hospital or patient died during hospitalization, 
or patient still in the hospital when study 
calendar time or patient follow up time ended.  
 
Dichotomous 
TIME  Time measured in number of days from the 
time of admission (origin) to the hospital to 
the day of discharge (event) from the hospital. 
 
Continuous 
FUROSEMI
DE 
The generic name of a type of a loop diuretic 
used. It denotes total 24-hour dose of 
Furosemide in mg given either IV continuous 
or IV Bolus in 1st 24 hours.  
 
Continuous 
URINE Total first twenty-four-hour urine output 
measured in mL after admission to the 
hospital. 
 
Continuous 
URINECAT Total 1st 24-hour urine output measured in 
mL after admission to the hospital divided 
into   
0=Non-aggressive Diuresis (less than 
or equal 2400mL urine output in 1st 
24-hour) 
Dichotomous 
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1=Aggressive Diuresis (more than 
2400mL urine output in 1st 24-hour). 
 
CR Serum creatinine measured in mg/dL on the 
day of admission to the hospital. 
 
Continuous  
CRCAT Serum Creatinine dichotomized into two 
categories 
0= less than or equal 1.6mg/dL 
(equivalent to stage 3 or less kidney 
disease) 
1= greater than 1.6 mg/dL (equivalent 
to stage 4 or greater kidney disease 
 
Dichotomous 
EF Ejection fraction of the left ventricle of heart 
on echocardiography (%). 
 
Continuous 
BP Systolic blood pressure at the time of 
admission to hospital in mmHg. 
 
Continuous 
CHF Type Congestive Heart Failure(CHF). 
0= Systolic CHF 
1=Diastolic CHF 
 
Dichotomous 
WORSEKID
NEY 
Worsening of kidney function during 
hospitalization. It is defined as 0.3 mg/dL 
increase in the creatinine or 50% increase in 
the creatinine from baseline (admission day) 
in 1st 24 hours. 
0=No worsening 
1=Yes worsening 
Dichotomous 
ARRHYTH
MIA 
Defined as atrial or ventricular 
tachyarrhythmia lasting greater than one 
minute. 
0=No  
1=Yes 
 
Dichotomous 
DEATH All-cause death from any cause. 
0=No 
1=Yes 
 
Dichotomous 
HYPOTENS
ION 
 Low blood pressure (less than 90mmHg) 
after 1st 24 hours. 
0=No 
1=Yes 
Dichotomous 
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2.7 SAMPLE SIZE AND POWER: 
Study size and power estimate will be based on the median number of days of 
hospital stay using the Log-Rank test method. Previously studies have noted median 
hospital stay of 7 days.4 We expect this median hospital stay in the hospital for the non-
aggressive cohort (to be reference group). We anticipate clinically crucial minimum 
effect size of 3 three-day difference. The Type I error level is chosen as 0.05 for the two-
sided hypothesis. The hospital has about 450 admissions with primary diagnosis of CHF 
each year. If we exclude 200 patients as a liberal guess not meeting inclusion criterion, 
then, we still have 100 patients in each arm which will give us the power of more than 
0.90. 
 The details of the Log-Rank test method were applied using SAS (see Appendix). 
Total study time will be one calendar year i-e January 1, 2014, to December 31, 2014. 
There will be no accrual period; patient follow up will be from the day of admission to 
the hospital to final discharge up to 30 days. It is anticipated that event of interest 
(discharge) will be observed in all the patients and there will be no correction for loss to 
follow-up, treatment discontinuation, and other forms of censoring. 
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SAS PROGRAM CODING AND OUTPUT: 
 
PROC POWER; 
TWOSAMPLESURVIVAL TEST=LOGRANK 
GROUPMEDSURVTIMES  = (4 7) 
    ACCRUALTIME = 0 
    FOLLOWUPTIME = 30 
    GROUPNS = 100 | 100 
    POWER = .; 
RUN;  
Power analysis of Length of Hospital Stay and Aggressive vs non-Aggressive Diuresis:  
 
The POWER Procedure 
Log-Rank Test for Two Survival Curves 
Fixed Scenario Elements 
Method Lakatos normal approximation 
Form of Survival Curve 1 Exponential 
Form of Survival Curve 2 Exponential 
Accrual Time 0 
Follow-up Time 30 
Group 1 Median Survival Time 4 
Group 2 Median Survival Time 7 
Group 1 Sample Size 100 
Group 2 Sample Size 100 
Number of Sides 2 
Number of Time Sub-Intervals 12 
Group 1 Loss Exponential Hazard 0 
Group 2 Loss Exponential Hazard 0 
Alpha 0.05 
 
 
Computed 
Power 
Power 
0.970 
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STUDY TIME:  
Stage 1: Review of medical Records 8 months. 
Stage 2: Data collection and data analysis 1-2 months. 
Stage 3: Presentation and publication 3-4 month. 
 
2.8 DATA MANAGEMENT: 
This is a retrospective review of medical records. Patient confidentiality will be 
maintained, and data will be de-identified. There will be no breach of subjects’ privacy. 
The retrospective review does not involve patient’s contact or consent since research 
does not involve more than minimal risk to subjects. Each patient will be assigned a 
unique identifier that will have no meaning to the study database (it will not incorporate 
subject name, medical record number). The patient identifier will be kept separately from 
main data. Principle investigator himself will transcribe data into the database. Only 
principle investigator and research mentors will have access to paper data entry forms 
and electronic database. Study database will be encrypted with a password, backed up 
regularly and will be stored offsite as well. 
   At the end of original study data, data dictionary and final data will be archived 
for three years for the investigator to respond to queries about the integrity of data or 
analysis. Any health care professional may request data provided University IRB 
approves it, and it complies with HIPAA. Principle investigator or research mentor may 
be contacted for this purpose. Patient data will be de-identified before that. 
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Missing values, outliers, and other data problems will be identified by using 
queries and will be cross-checked with medical records. 
   Crossfield validation will also be done for values within allowed ranges but 
inconsistent with one another. 
   We will maintain the audit log for all data changes. Editing procedure will be 
repeated with few errors identified, and then data will be finalized and or frozen so that 
no further changes can be made. 
MISSING DATA: 
Although every effort will be made to avoid missing data, patients with missing 
data will be compared to patients with complete data to describe potential bias due to 
differential loss of data. We will also explore methods for imputing missing data using 
maximum likelihood methods and will apply these in the presence of incomplete and 
missing data to reduce bias and increase the precision. 
2.9 STATISTICAL ANALYSIS PLAN:  
  We propose to evaluate the association between aggressiveness of diuresis and 
length of hospital stay. 
Univariate Analysis: 
We will present the number and percent of subjects included in the study 
population before exclusion. Univariate analysis will be done to look for outliers and 
ranges. We will do normality test by using Shapiro Wilk test statistically and Q-Q plot 
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visually. Normally distributed data will be presented as mean and standard deviation and 
the non-normal data as median and interquartile(IQ) range. We will present categorical 
data as frequencies and percentages of the total. 
Bivariate Analysis:  
We will cross-tabulate covariates with exposure and outcomes for sensitivity 
analysis to address any potential bias and confounding. Cross with exposure (aggressive 
vs. non-aggressive group) will be evaluated with the Chi-square test to determine whether 
the observed distribution fits the expected distribution when the cell size is sufficient. 
When the cell size is not enough Fisher’s exact test will be used. P values reflecting the 
differences in distribution will be presented for all the covariates.  For continuous 
covariates, independent samples t-test will be used to compare the mean between two 
aggressive and non-aggressive groups for normally distributed data whereas Mann-
Whitney U test will be used for non-normal data. Confidence intervals for the difference 
between two medians will be calculated using Hodges-Lehmann estimates. 
   Non-parametric Kaplan Meier method will be used to compare the proportion of 
patients discharged from the hospital (or 1- accumulated proportion of patient still in 
hospital) between aggressive versus non-aggressive diuresis group. Survival curves will 
be compared using Log Rank and Breslow tests. Cox proportional hazards regression will 
be used to calculate the univariate hazard ratio(HR) for the covariates significantly 
associated with mortality and length of hospital stay. 
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Multivariable analysis: 
In multiple linear regression model we will define the predictors of 24-hour urine 
output by regressing the 24-hour urine output as a continuous outcome variable on 24 
hours Furosemide dose including potential confounders in the model. We will include an 
interaction term between CKD and Furosemide. Backward Elimination method will be 
used to obtain the final model. 
Cox proportional hazards regression analyses will be used to estimate Hazard 
Ratio and 95% CI for Hazard Ratio of hospital discharge in aggressive vs. non-aggressive 
diuretic therapy group. We will obtain variables for multivariable Cox proportional 
model via entry of all univariate baseline predictors of discharge from hospital with a 
value of P<0.2 and predictors first twenty-four hours urine output from multivariable 
linear regression model mentioned earlier. Using backward selection and starting with a 
variable with the largest P value, we retained variables that altered the HR by >10 % in 
the final model. Proportional- hazards assumption will be tested by visual inspection of 
log-minus-log survival plots and cumulative martingale residue plot. The main effects 
and all covariates found to be in violation of the proportional- hazards assumption will be 
appropriately transformed.  
Statistical analysis will be performed with SPSS version 24.0 (SPSS Inc, Chicago, 
IL) and SAS version 9.4 (SAS Inst., Cary, NC) Significance will be defined as the 2-
tailed value of P<0.05. 
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RESULTS: 
   483 patients met screening criterion initially. We excluded 289 cases because of 
age above 80 years of age, dialysis dependent End Stage Renal Disease (ESRD) and 
other acute medical illness concurrently (See Figure1). 194 cases were included in the 
analysis. 165 met criterion of non-aggressive diuresis and 29 met criterion for aggressive 
diuresis. Follow up was complete in all cases. Six patients died in the non-aggressive 
group because of unrelated causes and were censored in time to event analysis. 
In the total cohort, total first maximum twenty-four hours urine output ranged 
from 110ml to 5800mL with mean 1372 ±1009 mL. Total maximum twenty-four hours 
Furosemide dose ranged from 40mg to 240mg with median dose 80 and IQ range of 40-
80. Total range of length of hospital stay was 1 to 28 days with a median of 5 days and 
IQ range of 3-8 days. 
Means of age (P=0.09), left ventricular ejection fraction (P=0.78) were 
comparable between aggressive and non-aggressive diuresis group. First twenty-four 
hours total dose of Furosemide used was significantly higher in aggressive diuresis 
groups as compared to non-aggressive diuresis group (P=0.049). Similarly, mean systolic 
blood pressure at admission (144 ± 23 versus 135±23; P=0.046)   and mean 24-hour urine 
output (3209 ±903 versus 1049± 598; P< 0.001) were significantly higher in aggressive 
diuresis group than the non-aggressive group. Distributions of sex, race, and type of heart 
failure were comparable between two groups (P>0.05). A smaller proportion of patients 
developed kidney dysfunction in non- aggressive diuresis group as compared to 
aggressive diuresis group, but it was not found to be statistically significant (6.9% versus 
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12.15%; P = 0.2). A smaller proportion of patients were found to have an episode of 
hypotension in the aggressive diuresis group as compared to the non-aggressive diuresis 
group, but it was not found to be statistically significant (6.9% versus 13.9 %; P=0.38). 
There were six deaths noticed in total in non-aggressive diuresis group only. Eight 
patients were noted to have an arrhythmia in the non-aggressive diuresis group as 
compared to 1 in aggressive diuresis group. 
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Table 2: Characteristics of Patients 
Characteristics Total Cohort Non-aggressive diuresis a 
Aggressive 
diuresis a P value 
Age(years)     
Mean(SD) 72(11) 72(10) 69(12) 0.09 
Race     
White 182(93.8%) 153(92.7%) 29 (100%) 0.22 
Non-white 12(6.2%) 12(7.3%) 0(0 %)  
Sex     
Male 96(49.5%) 80 (48.5%) 16 (55.2%) 0.51 
Female 98(50.5%) 85 (51.5%) 13 (44.8%)  
Type of Congestive 
Heart Failure 
    
Systolic 112(57.7%) 96(58.2%) 16(55.2%) 0.76 
Diastolic 82(42.3%) 69(41.8%) 13(44.8%)  
Left Ventricular 
Ejection Fraction (%)     
Mean(SD) 40(16) 40(16) 41(15) 0.78 
Systolic Blood pressure 
on Admission (mmHg)     
Mean(SD) 137(23) 135(23) 144(23) 0.046* 
Creatinine at Time of 
Admission mg/dL)     
Mean(SD) 1.33(0.57) 1.33(0.56) 1.31(0.63) 0.86 
Dose of Furosemide 
used(mg) † 
    
Median(IQ) 80(40-80) 70(40-80) 80(55-120) 0.049* 
24 Hour Urine 
output(mL) 
    
Mean(SD) 1372(1009) 1049(598) 3209(903) <0.001* 
Worsening of Kidney 
Function 
    
Yes 22(11.3%) 20 (12.15%) 2(6.9%) 0.54 
No 172(88.7%) 145(87.9%) 27(93.1%)  
Hypotension     
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Yes 25(12.9%) 23(13.9%) 2(6.9%) 0.38 
No 169(87.1%) 142(86.1%) 27(93.1%)  
Death     
Yes 6(3.1%) 6(3.6%) 0(0%) 0.59 
No 188(96.9%) 159(96.4%) 29(100%)  
Arrhythmia     
Yes 9(4.6%) 8(4.8%) 1(3.4%) 1 
No 185(95.4%) 157(95.2%) 28(96.6%)  
P value refers to the difference between aggressive and non-aggressive diuresis groups. 
*Significant 
†Loop diuretic dose reported as median with interquartile range; all other values represent mean±SD or %. 
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The final multivariable linear regression model after backward elimination 
showed statistically significant main effect (P<0.001) of a dose of Furosemide in 
increasing first twenty-four hours urine output along with its interaction with creatinine at 
the time of admission, depicting higher dose of Furosemide required to produce the same 
amount of urine with greater than 1.6mg/dL creatinine on admission. (P=0.02). See Fig 2, 
Table 3. 
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Table 3: Multiple Linear Regression model with 24 Hour Urine output regressed 
 on Dose of Furosemide, Creatinine at the time of Admission  
Characteristics Coefficient Standard 
Error 
95% CI t P 
intercept 556.88 190.91 180.31 to 933.45 2.91 0.004 
Furosemide 12.14 2.43 7.35 to 16.94 5.00 <0.001
* 
Cr > 1.6 395.26 322.42 -240.73 to 1031.25 1.23 0.22 
Cr >1.6 X 
Furosemide 
-8.98 3.47 -15.83 to -2.14 -2.59 0.02* 
 
Furosemide, Total 24 hours dose of Furosemide used in 24 hours; Cr>1.6, indicates greater than 1.6 mg/dL 
serum creatinine at time of admission equivalent to stage 3 or less kidney disease; Cr>1.6 X Furosemide, 
indicates interaction between furosemide and creatinine greater than 1.6mg/dL.*Significant 
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Kaplan Meier estimate of the median accumulated proportion of patients still in 
hospital in aggressively diuresed patients(n=29) was 4 days as compared to 5 days in 
non-aggressively diuresed patients (n=165). Log–Rank test (P=0.67) and Breslow test 
(0.77) revealed non-significant differences between the accumulated hospitalized 
proportion over time. 
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Table 4 Summary of Kaplan – Meir Estimate for Cohort- total Study Sample of 194 
Patients 
Time 
(days) 
Accumulated 
Proportion 
patient in 
Hospital (%) 
95% CI 
(%) 
Number of 
patients 
discharged 
Number 
patients 
censored 
Number 
at Risk 
2 0.80 0.74 to 0.86 38 0 156 
4 0.53 0.45 to 0.61 91 2 101 
6 0.32 0.26 to 0.38 131 0 61 
8 0.20 0.15 to 0.26 153 1 38 
10 0.15 0.09 to 0.21 163 1 27 
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Table 5 Survival Characteristics of subgroup of Study Sample 
Group 
No of 
total 
Patients 
Total Number of 
Patients 
Discharged 
Total 
Number 
Censored 
Median 
Hospital stay in 
days 
95% (CI) 
Aggressive diuresis 29 29 0 4 (2.95 to 5.06) 
Non-aggressive 
Diuresis 165 159 6 5 (4.40 to 5.60) 
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Table 6 Univariate Cox Proportional Hazards Regression Model Showing effect of 
Aggressive Diuresis on Risk of Discharge from Hospital. 
Characteristics Coefficient Standard Error 
Wald 
χ2 
P 
value 
Hazard 
Ratio 
95% 
CI 
Aggressive 
diuresis 0.079 0.20 0.15 0.70 1.08 
0.73 to 
1.61 
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Table 7: Cox Proportional Hazards Regression Model Showing the Effect of Four 
Variables on Risk of Discharge from Hospital 
 
Characteristics Coefficient Standard Error 
Wald 
χ2 
P 
value 
Hazard 
Ratio 
95% 
CI 
Aggressive 
diuresis 0.11 0.21 0.27 0.60 1.12 
0.74 to 
1.68 
LVEF 0.007 0.005 2.19 0.14 1.01 1.00 to 1.017 
Furosemide <0.001 0.003 0.001 0.98 1.000 0.995 to 1.005 
Cr >1.6 -0.10 0.33 0.10 0.75 0.90 0.47 to 1.72 
Cr >1.6 X 
Furosemide 0.001 0.004 0.07 0.79 1.001 
0.99 to 
1.01 
Aggressive diuresis, indicates greater than or equal 2400mL/ 24 Hour urine; LVEF, Left 
Ventricular Ejection Fraction; Furosemide, Total 24 hours dose of furosemide used in 24 hours; 
Cr>1.6, indicates greater than 1.6 mg/dL serum creatinine at time of admission equivalent to 
stage 3 or less kidney disease; Cr>1.6 X Furosemide, indicates interaction between furosemide 
and creatinine greater than 1.6mg/dL. 
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In univariate analysis, Cox proportional hazards regression showed the unadjusted 
hazard rate of discharge from hospital was similar to patients with aggressive diuresis, as 
results did not approach statistical significance (HR=1.08; P=0.70). Similarly, in 
multivariate Cox model creatinine at the time of admission when greater than 1.6mg/dL 
(P=0.75), left ventricular ejection fraction (P= 0.14), total 24 hours dose of furosemide 
given (P=0.98)   and interaction between Furosemide and Creatinine (P=0.79) were not 
statistically significant. The hazard rate of discharge from Hospital was 12% higher in 
aggressive diuresis group then non-aggressive diuresis but still statistically non-
significant (adjusted HR=1.12; P=0.6). 
DISCUSSION:  
A diuretic is a primary agent used in acute CHF.  The effect of a diuretic on urine 
output is modified by patient-related comorbidities and concurrent administration of other 
medications. It is a common observation that the dose required for the same amount of 
diuresis varies not only between patients with similar comorbidities but additionally 
within the same patient during different hospitalizations. Loop diuretics over a period can 
lead to diuretic resistance with persistent fluid overload. It is likely from the activation 
renin-angiotensin-aldosterone system and sympathetic nervous system, hence reducing 
renal blood flow, decreasing the filtered sodium and increasing its reabsorption. Chronic 
loop diuretic therapy also leads to hypertrophy of epithelial cells in the distal tubules thus 
increasing sodium absorption 9,10. Other factors responsible are decreased drug delivery 
to nephron and hyperchloremia.11 These mechanisms make dose response unpredictable. 
Despite this heterogeneity in responses, ROSE randomized controlled trial which 
recruited patients with advanced heart failure showed the effect of diuresis of loop 
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diuretic to be unchanged even if combined with other medications. In this RCT one of the 
primary endpoints was the 72-hour cumulative urine volume as an index of diuresis. 
After 72-hours study investigators did not find a difference in total median dose of 
diuretic required as well as cumulative urine output in three combination groups (placebo 
with furosemide, low-dose dopamine with furosemide, and low-dose nesiritide with 
furosemide). 6,12  Extending the same concept to our study and ignoring the use of other 
medication, as expected the group with higher diuresis (aggressive diuresis group) had a 
higher median dose of diuretic than the non-aggressive group. We found a linear 
relationship between the loop diuretic dose and first twenty-four hours urine output 
modified by worse kidney dysfunction. As higher urine output would lead to early relief 
of symptoms with congestion, we expected an earlier discharge of a patient with higher 
first twenty-four hours urine output, however to our surprise, there was no statistically 
significant difference between the hazards of discharge of the patients in two groups. 
There appeared to be a disconnect, as high diuresis achieved in first twenty-four hours 
did not translate into a shorter hospital stay. There can be many explanations.  Length of 
hospital stay might have been affected by the subsequent different daily dose of diuretic 
depending on the clinical course. Patients in the non-aggressive diuretic therapy group 
with lesser urine output might have had incomplete relief of congestion, and in turn had 
to be given smaller doses for a longer period thus increasing the length of hospital stay. 
On the other hand, the patients who were in the aggressive diuresis therapy group might 
have had adverse effects as worsening of kidney function, hypotension or electrolyte 
disturbances, notorious with a higher diuretic dose thus might have required subsequent 
dose reduction leading to less urine ouptut.13-16 Number of adverse effect in each group 
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are not reliable in our study as these were counted in the first twenty-four hours only and 
study was not powered to detect the adverse outcome difference. It appears that the 
advantage of increased urine output in the first twenty-four hours was offset by the low 
urine output in subsequent days, leading to comparable total days of hospital stay. 
 Secondary analysis of ESCAPE trial showed that when aggressive diuretic 
therapy was used, excess reduction in the intravascular volume measured by surrogate 
markers of hemoconcentration and protein concentration directly correlated with 
worsening of kidney function. After aggressive diuresis with higher dose there a was a 
greater change in weight (fluid loss) leading to decrease in pulmonary wedge pressure 
and right atrial pressure, as well as poor perfusion to kidneys and worsening kidney 
function likely explaining cardiorenal syndrome.17 Similarly, a higher dose of loop 
diuretic theoretically leads to hemodynamic disturbance causing hypotensive episodes 
due to reduced cardiac index and reduction in filling.  DOSE trial used a 2-by-2 factorial 
design to test Furosemide in low vs. high dose as a  continuous IV vs. bolus IV dose to 
find a difference in primary endpoints of improvement in patient symptoms and 
worsening of renal function in any specific group.7 The study found no difference in 
primary endpoints as well as a one of its prespecified secondary endpoint; the length of 
hospital stay. Since our study has shown a linear relationship between urine output and 
the dose of Furosemide modified by baseline creatinine, we can safely argue that there 
was higher urine output in high dose arm of  Furosemide DOSE trial as there was no 
difference in baseline creatinine in any group. Despite higher urine output, it did not 
result in a shorter hospital stay. It corresponds with our finding that amount of diuresis 
predicts the degree of decongestion and relief of symptoms better than the surrogates; the 
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amount of loop diuretic used directly. The amount of urine output still does not influence 
the length of hospital stay. Howard and Dunn conducted a non-randomized prospective 
study on >65-year old patient with NYHA class IV CHF. Treatment arm involved 
aggressive diuretic therapy in achieving the goal of ≥ 2400/24hours urine output. This 
lead to a shorter hospital stay of 2.3 days and lesser cost than the non-aggressive 
(standard medical care group). Results in that study are appealing but likely biased due to 
the use of particular subset population in the treatment group, a small sample of 17 only, 
non-randomized design and differential close monitoring of the intervention group for the 
signs of decongestion, adverse effects as well as prompt replacement of electrolytes 
especially chloride to avoid resistance. 3 Li and Hong in China conducted a similar 
retrospective cohort study design on 195 patients.  After implementing same cutoffs to 
define the aggressive diuretic therapy as urine output of  ≥ 2400mL/24 hour, they found a  
shorter length of hospital stay(aggressive diuretics therapy: 11 days vs. non-aggressive 
therapy: 16 days; P< 0.05 ).8  Although the study has a similar design as our study results 
are different possibly because the average length of hospital stay in their groups was 13.5 
days much higher than our mean duration of 5 days for our total study cohort. It is likely 
related to the intrinsic difference in population or treatment difference in two countries. 
In ESCAPE Trial, aggressive diuresis  using the pulmonary wedge pressure based 
monitoring method vs standard clinical assessment method did  not show significant 
difference in endpoint of total 6 months mortality after randomization  as well as 
difference in prespecified endpoint of mean number of days hospital stay (aggressive 
diuretics therapy: 8.7 days vs  non aggressive therapy : 8.3 days; P= 0.67 ). There was no 
comparison of the urine output in the groups, but we can argue that pulmonary wedge 
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pressure directed group had higher urine output, but still there was no difference in length 
of hospital stay17,18.  
LIMITATIONS: 
Our study has inherent limitations of any retrospective study. Since it not 
prospective blinded RCT study and all patient were a subset of all acute CHF patient 
from a single center meeting inclusion criterion, results of this study might have some 
selection bias and all unknown confounders might not have been controlled. Patients 
were included with first-time hospital admission or on readmission with a primary 
diagnosis of acute CHF, but other coexistent comorbidities potentially complicating the 
hospital course were not included. We did not have data on weight, dietary sodium and 
fluid intake, or BNP levels in patients at the time of admission. Since diuretic dose and 
urine output was limited to first twenty-four hours and not during complete hospital 
course, it limits the ability to determine the temporal relationship between urine output 
and length of hospital stay. The proportion of patient in each group were not equal as 
expected during the assessment of the power of study, thus it will affect the actual total 
power study was able to achieve.  
 
CONCLUSION: 
To date, clinicians have no clear evidence-based strategies for safely and rapidly 
improving congestion in patients with acute CHF. Our study showed higher diuretic dose 
based on the inherent desire to increase diuresis for a quicker relief of symptoms is 
associated with higher urine output and possibly untoward adverse effects during the 
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hospital course. Thus patients with higher and low urine output tend to stay a comparable 
total number of days in the hospital. Although these results are in line with the possible 
pathological mechanism, there were methodological limitations with small sample size. 
As a result, we suggest challenging rather than changing current conceptions about 
monitoring the diuresis in a patient with dose of loop diuretic rather than the amount of 
urine output. Future research necessary in large prospective randomized controlled trials 
to assess the direct effect of amount diuresis rather than the dose of diuretics in the relief 
of signs or symptoms or radiological improvement in congestion, readmission, mortality, 
biochemical parameters and cost of hospital admission. We suggest an adequate dose of 
diuretic to keeping the goal of daily diuresis less than 2400mL/24 hours.  
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